Attributes | Values |
---|
rdf:type
| |
Description
| - Byl sledován vliv silymarinu na lipidový profil v plazmě a antioxidační kapacitu séra. Dobrovolníci (muži, n=29) byli rozděleni do 2 skupin. Účastníci ve skupině 1 (n=17) dostávali 858 mg/den silymarinu a ´ve skupině 2 (n=12) placebo. Každému dobrovolníkovy byla odebráne krev (den 1., 30. a 60.). U skupiny 1 byl zjištěn nárůst HDL cholesterolu a Apo A1 a pokles celkového a LDL cholesterolu. (cs)
- A study was conducted to determine the effects of silymarin on plasma lipids and serum antioxidant capacity in man. 29 study volunteers were randomly divided into 2 groups of 17 and 12 and were given 858 mg/day of silymarin or placebo, respectively. 3 blood samples were taken from each participant, in days 1, 30 and 60. An increase in the trend in HDL-cholesterol , ApoA1 and a decrease of total cholesterol and LDL-cholesterol was foudn in the silymarin group in comparison with the placebo group. Changes in lipid peroxidation parameters between the silymarin group and the placebo group were statistically insignificant. Results suggest possibilities to use the combination of silymarin with currant oil as a nutraceutical, beneficial for the prevention of risk factors of atherosclerosis.
- A study was conducted to determine the effects of silymarin on plasma lipids and serum antioxidant capacity in man. 29 study volunteers were randomly divided into 2 groups of 17 and 12 and were given 858 mg/day of silymarin or placebo, respectively. 3 blood samples were taken from each participant, in days 1, 30 and 60. An increase in the trend in HDL-cholesterol , ApoA1 and a decrease of total cholesterol and LDL-cholesterol was foudn in the silymarin group in comparison with the placebo group. Changes in lipid peroxidation parameters between the silymarin group and the placebo group were statistically insignificant. Results suggest possibilities to use the combination of silymarin with currant oil as a nutraceutical, beneficial for the prevention of risk factors of atherosclerosis. (en)
|
Title
| - Perspective nutraceutical - milk thistle extract with polyunsaturated fatty acids
- Perspective nutraceutical - milk thistle extract with polyunsaturated fatty acids (en)
- Perspektivní nutraceutikum - extrakt z ostropestřce mariánského s polynenasycenými mastnými kyselinami (cs)
|
skos:prefLabel
| - Perspective nutraceutical - milk thistle extract with polyunsaturated fatty acids
- Perspective nutraceutical - milk thistle extract with polyunsaturated fatty acids (en)
- Perspektivní nutraceutikum - extrakt z ostropestřce mariánského s polynenasycenými mastnými kyselinami (cs)
|
skos:notation
| - RIV/61989592:15110/01:00006009!RIV09-MZ0-15110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(NL6713), Z(MSM 151100003)
|
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/01:00006009
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Silybum marianum; human; LDL; HDL; cholesterol (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/mistoVydani
| |
http://linked.open...i/riv/nazevZdroje
| - Biologically-active Phytochemicals in Food. Analysis, Metabolism, Bioavailability and Function.
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| - Ulrichová, Jitka
- Šimánek, Vilím
- Škottová, Nina
|
http://linked.open...n/vavai/riv/zamer
| |
number of pages
| |
http://purl.org/ne...btex#hasPublisher
| - The Royal Society of Chemistry
|
https://schema.org/isbn
| |
http://localhost/t...ganizacniJednotka
| |